Últimas noticias sobre Eli Lilly (NYSE:LLY) Bolsa

Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co

Equities

News

Markets

APLD

MSFT

RGTI

TSLA

Descubre cómo las acciones de Microsoft, Tesla y Rigetti lideraron el movimiento del mercado en una jornada de contrastes.

Microsoft, Applied Digital, Rigetti Computing, Eli Lilly, Tesla: 5 valores que están en el radar de los inversores

Trading Ideas

Elon Musk respalda Mounjaro en la batalla contra Ozempic. ¿Qué implican sus opiniones para la industria de pérdida de peso?

Medicamentos para adelgazar: La batalla entre Mounjaro y Ozempic con Elon Musk como protagonista

Biotech

Large Cap

Health Care

Movers

General

Novo Nordisk revela datos sobre Amycretina, un nuevo medicamento para pérdida de peso, que mostró una baja del 13,1% en peso en 12 semanas.

Novo Nordisk presenta resultados de su nuevo fármaco para pérdida de peso, Amycretina

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live Group

LIBERTY LIVE SERIES B by Liberty Media Corporation

Liberty Media Corporation - Series C Liberty Live Common Stock

Tidal Trust II Defiance Daily Target 2X Long LLY ETF

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has outperformed the market over the past 20 years by 6.03% on an annualized basis producing an average annual return of 14.45%. Currently, Eli Lilly has a market capitalization of $740.34 billion. 
Buying $100 In LLY: If an investor had bought $100 of LLY stock 20 years ago, it would be worth $1,476.91 today based on a price of $823.23 for LLY at the time of writing.
<h3>Eli Lilly's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738280753_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Robert F. Kennedy Jr., President Donald Trump's pick for health secretary, addressed a wide range of medical-related topics on Wednesday during a confirmation hearing with <a href="https://www.benzinga.com/25/01/43306674/trumps-hhs-pick-robert-kennedy-jr-begins-senate-confirmation-hearings">the Senate Finance Committee.</a>
While Kennedy&#8217;s tone in each back-and-forth varied, depending on the senator, it was evident that Kennedy&#8217;s role in the new administration would have a tremendous impact on both pharma and insurance stocks.
<h3 class="wp-block-heading">Drug Price Negotiation</h3>
During one exchange about the high cost of drugs with Senator Catherine Cortez Masto (D-NV), Kennedy said: "Senator, my understanding is that the White House issued an executive order, I believe today, supporting the drug negotiations under the I.R.A. President Trump was very aggressive during his first term about negotiating drug prices."
In reality, Trump has not signed an executive order on the topic since he was sworn into office. A Wednesday news <a href="https://www.cms.gov/newsroom/press-releases/cms-statement-lowering-cost-prescription-drugs" target="_blank" rel="noreferrer noopener">release</a> from the Centers for Medicare and Medicaid Services said that lowering the cost of prescription drugs for Americans &#8220;a top priority&#8221; for the Trump administration and that he would work to improve the transparency of the negotiation process.
Perhaps Kennedy was recalling Trump&#8217;s first term. In 2020, then-45th President Trump <a href="https://www.benzinga.com/general/biotech/20/09/17482940/trump-signs-executive-order-to-lower-us-drug-prices-after-negotiations-with-drugmakers-fail">signed an executive order</a> on U.S. Medicare drug prices intending to reduce costs. Industry leaders, including Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) CEO Albert Bourla, criticized the move. Pfizer was seeking regulatory approval to expand its late-stage vaccine trial at the time.
If Trump signs such an order, it would be a rare show of support from his camp for a Biden-era initiative. In addition to Pfizer, it would also impact major companies like Bristol Myers Squibb, Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), Novartis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) and AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>).
Last month, the Biden administration <a href="https://www.benzinga.com/25/01/43062779/popular-ozempic-wegovy-selected-for-next-round-of-medicare-drug-price-negotiations">identified the next 15 drugs</a> as subject to negotiation. The list included Ozempic and Wegovy — two expensive drugs for diabetes and obesity owned by Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
See Also: <a href="https://www.benzinga.com/25/01/43306674/trumps-hhs-pick-robert-kennedy-jr-begins-senate-confirmation-hearings">RFK Jr. Is A &#8216;Predator&#8217; Unfit For Office, Caroline Kennedy Says </a>
<h3 class="wp-block-heading">Insurance Providers</h3>
According to the <a href="https://www.nytimes.com/live/2025/01/29/us/rfk-jr-health-senate-hearing">New York Times</a>, Kennedy wasn&#8217;t exactly familiar with Medicare and Medicaid, but expressed support for Medicare Advantage, where private insurers provide coverage for elderly Americans.
Kennedy also called out what he considered to be &#8220;rapacious behavior by insurance companies." He even suggested he would support some of the efforts undertaken during the Biden administration to crack down on abusive tactics like denying care and overcharging the government.
Traders would be wise to keep an eye on how insurance stocks — especially those tied to Medicaid and Medicare providers — react if Kennedy is sworn in. The major players in this space include: 
UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), the largest Medicare Advantage insurer in the U.S.; Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>); Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), one of the largest Medicaid managed care organizations; Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>); CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>); Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>); and Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>).
What&#8217;s Next: Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people.
The title also puts him in charge of the Food and Drug Administration, the National Institutes of Health and the Centers for Disease Control and Prevention.
He will appear before the Senate Committee on Health, Education Labor and Pensions on Thursday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/25/01/43216758/well-go-as-far-as-im-allowed-trumps-plan-with-immigrants-starts-with-1-million-deportations" target="_blank" rel="noreferrer noopener">‘We'll Go As Far As I'm Allowed': Trump's Plan With Immigrants Starts With 1 Million Deportations</a></li>
</ul>
Image: Shutterstock

Politics

Insurance

ABBV

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) is a &#8220;very <a href="https://www.benzinga.com/quote/FSLR/earnings">inexpensive&#8221; stock</a>.
First Solar, meanwhile, will report financial results for the fourth quarter and full year ended Dec. 31, 2024, after the closing bell on Tuesday, Feb. 25, 2025.
<h3 class="wp-block-heading">Shares His Views On These Health Care Stocks</h3>
When asked about Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), Cramer said he prefers Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
In the recent news, Viking Therapeutics, on Jan. 8, announced the initiation of Phase 2 VENTURE-oral dosing trial of VK2735 tablet formulation in patients with obesity.
&#8220;This group is just not strong enough, that includes this one. Let's give it a pause for a second,&#8221; Cramer said when asked about RadNet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>). &#8220;It was a great stock for a long time, I need to see a real bottom.&#8221;
Barclays analyst Andrew Mok, on Jan. 22, maintained RadNet with an Overweight rating and lowered the price target from $85 to $74, while Truist Securities analyst David Macdonald reiterated the stock with a Buy and slashed the price target from $94 to $88.
<h3 class="wp-block-heading">Likes This Industrial Stock Very Much</h3>
The &#8220;Mad Money&#8221; host said he likes Waste Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) very much, adding that it's an &#8220;absolutely terrific&#8221; stock. He added, &#8220;I would start a position right now.&#8221;
Supporting his view, Scotiabank analyst Konark Gupta, on Monday, upgraded Waste Management from Sector Perform to Sector Outperform and raised the price target from $225 to $250.
Price Action:
<ul>
<li>Viking Therapeutics shares gained 2.6% to settle at $34.32 on Tuesday.</li>
<li>First Solar shares fell 2.5% to close at $160.24 during the session.</li>
<li>RadNet shares gained 4.2% to settle at $65.94 on Tuesday.</li>
<li>Waste Management shares rose 0.01% to settle at $213.65 on Tuesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43263799/wall-streets-most-accurate-analysts-spotlight-on-3-tech-telecom-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Tech &amp; Telecom Stocks Delivering High-Dividend Yields</a></li>
</ul>
Image: Shutterstock

Media

FSLR

RDNT

VKTX

Jim Cramer: This Industrial Stock Is 'Absolutely Terrific', First Solar Is 'Very Inexpensive'

Note: This story has been updated with additional details on recent moves by tech titans.
Rep. Marjorie Taylor Greene (R-Ga.) <a href="https://www.benzinga.com/insights/government/25/01/43271358/georgia-rep-marjorie-taylor-greene-bought-over-1k-worth-of-asml-holding-stock-heres-what-you-">disclosed</a> a series of new trades as President Donald Trump&#8216;s equations with the leaders of Big Tech companies and other firms evolve during his second term. Greene&#8217;s portfolio shows the addition of 14 stocks and U.S. Treasuries, in a disclosure dated Jan. 27.
What Happened: The Republican politician, Greene, who has been the representative of Georgia&#8217;s 14th congressional district since 2021 has added a total of five lots of Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), with a transaction value of $1,001-$15,000 each to her portfolio in 2025, with the most recent trade on Jan. 21.
According to Benzinga&#8217;s government trades <a href="https://www.benzinga.com/gov-trades/members/marjorie-taylor-greene">tracking tool</a>, Taylor Greene also owns two lots of Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), with the recent purchase valued at $1,001-$15,000 on Jan. 21.
Whereas, Green purchased Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) for the first time in 2025 on Jan. 21, valued at around $1,001-$15,000, ahead of the Federal Reserve&#8217;s interest rate decision
Here&#8217;s a summary of Greene&#8217;s trades on Jan. 21:
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Stocks/Bonds Purchased</td>
<td>Amount</td>
</tr>
<tr>
<td>Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Cardinal Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Devon Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Eli Lilly And Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Kinder Morgan Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>NextEra Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Norfolk Southern Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Occidental Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Old Dominion Freight Line Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Palo Alto Networks Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>US Treasury Bills</td>
<td>$50,001-$100,000</td>
</tr>
</tbody>
</table>
</figure>
While she owned two lots of Palo Alto Networks worth $1,001-$15,000 and one lot of U.S. Treasury bills worth $100,001-$250,000, all other purchases in the list are the most recent, dated Jan. 21.
See Also: <a href="https://www.benzinga.com/25/01/43295664/nvidia-supplier-asml-beats-q4-earnings-as-ceo-says-ai-is-key-driver-for-growth-is-it-a-buy-sell-or-hold-heres-what-technical-analysis-suggest">Nvidia Supplier ASML Beats Q4 Earnings Estimates, CEO Says &#8216;AI Is Key Driver For Growth:&#8217; Buy, Sell, Or Hold? Here&#8217;s What Technical Analysis Suggests </a>
Apart, from these stocks, she had investments worth $1,001-$15,000 in three lots of Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>), and Caterpillar Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) in 2025.
She also held one lot worth $1,001-$15,000 in Home Depot Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>), iShares Bitcoin Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>), Southern Copper Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>), Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>), and two lots worth the same in United Parcel Service Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) and Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), in 2025.
Lastly, in 2025, she owned four lots of the same amount in JPMorgan Chase &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) and Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
Why It Matters: Members of Congress, both senators and representatives must publicly <a href="https://www.benzinga.com/insights/government/25/01/43271358/georgia-rep-marjorie-taylor-greene-bought-over-1k-worth-of-asml-holding-stock-heres-what-you-">disclose</a> any personal stock trades they make. This means they have to file a report whenever they buy or sell stock.
The STOCK Act, which became law in 2012, requires these reports to be filed within 45 days of the transaction and also mandates monthly disclosures of their financial holdings. This law aims to prevent insider trading by making sure Congress members don&#8217;t use their privileged information for personal profit in the stock market.
Major tech titans, including Tesla&#8217;s Elon Musk, Amazon&#8217;s Jeff Bezos, Meta&#8217;s Mark Zuckerberg, Apple&#8217;s Tim Cook, And Google&#8217;s Sundar Pichai have been visiting President <a href="https://www.benzinga.com/news/25/01/42935628/mark-zuckerberg-meets-donald-trump-at-mar-a-lago-mending-fences-ahead-of-gop-white-house-return">Trump's Mar-a-Lago </a>residence, reportedly seeking to shape future tech policies. 
Following Trump's victory in the 2024 U.S. presidential election, major tech leaders are shifting their strategies to align with the new administration. Zuckerberg <a href="https://www.benzinga.com/tech/25/01/42779753/mark-zuckerbergs-meta-replaces-global-affairs-chief-nick-clegg-with-republican-joel-kaplan-ahead-of-trump-inauguration">appointed Republican</a> Joel Kaplan to lead policy and donated $1 million. Google, Amazon, and Apple followed suit with similar contributions. Microsoft's Satya Nadella, who reportedly gave $500,000 to Trump&#8217;s first inauguration, is also engaging with the new administration to strengthen relations.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43263070/deepseek-buzz-batters-big-tech-but-this-analyst-says-buy-the-dip-heres-a-list-of-top-five-semiconductor-etfs-with-the-lowest-expense-rations-that-investors-could-consider">DeepSeek Buzz Batters Big Tech But This Analyst Says &#8216;Buy The Dip:&#8217; Here&#8217;s Are Top 5 Semiconductor ETFs With The Lowest Expense Ratios That You Can Consider </a></li>
</ul>
Photo courtesy: Shutterstock

Market Summary

Sector ETFs

Bonds

ETFs

AMZN

GOOG

IBIT

INTC

NVDA

ODFL

PANW

SCCO

Marjorie Taylor Greene Loads Up On Meta, Amazon, Tesla, Nvidia And Other Stocks As Donald Trump's New Equations With Big Tech Leaders Sets Stage For Growth: What Is At Stake? (UPDATED)

Deep-pocketed investors have adopted a bearish approach towards Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LLY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 21 extraordinary options activities for Eli Lilly. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 23% leaning bullish and 66% bearish. Among these notable options, 4 are puts, totaling $432,164, and 17 are calls, amounting to $1,185,751.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $460.0 to $1000.0 for Eli Lilly during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Eli Lilly's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly's whale trades within a strike price range from $460.0 to $1000.0 in the last 30 days. 
<h3>Eli Lilly Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738077326_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$50.0</td>
<td>$48.8</td>
<td>$48.8</td>
<td>$780.00</td>
<td>$244.0K</td>
<td>1.4K</td>
<td align="right">51</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/31/25</td>
<td>$9.75</td>
<td>$8.7</td>
<td>$8.7</td>
<td>$815.00</td>
<td>$185.7K</td>
<td>5</td>
<td align="right">208</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$173.2</td>
<td>$170.2</td>
<td>$170.2</td>
<td>$800.00</td>
<td>$170.2K</td>
<td>163</td>
<td align="right">10</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$153.9</td>
<td>$152.3</td>
<td>$153.9</td>
<td>$660.00</td>
<td>$153.9K</td>
<td>51</td>
<td align="right">10</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$40.55</td>
<td>$38.3</td>
<td>$40.55</td>
<td>$720.00</td>
<td>$101.3K</td>
<td>389</td>
<td align="right">25</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
After a thorough review of the options trading surrounding Eli Lilly, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Eli Lilly</h3>
<ul>
<li>With a volume of 339,987, the price of LLY is down -0.05% at $807.75. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 9 days.</li>
</ul>
<h3>Professional Analyst Ratings for Eli Lilly</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $1080.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Eli Lilly, targeting a price of $970. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on Eli Lilly with a target price of $1190. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Market Whales and Their Recent Bets on LLY Options

During the last three months, 7 analysts shared their evaluations of Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $1035.29, along with a high estimate of $1190.00 and a low estimate of $970.00. Highlighting a 5.02% decrease, the current average has fallen from the previous average price target of $1090.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1738069255_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Eli Lilly's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$970.00</td>
<td>$1000.00</td>
</tr>
<tr>
<td>Peter Verdult</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1190.00</td>
<td>$1250.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$997.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexandria Hammond</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$1000.00</td>
<td>-</td>
</tr>
<tr>
<td>James Shin</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1015.00</td>
<td>$1025.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$975.00</td>
<td>$1025.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1100.00</td>
<td>$1150.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Eli Lilly. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Eli Lilly compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Eli Lilly's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Eli Lilly's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LLY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Eli Lilly analyst ratings.</a>
<h2>All You Need to Know About Eli Lilly</h2>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Financial Insights: Eli Lilly</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3 months period, Eli Lilly showcased positive performance, achieving a revenue growth rate of 20.43% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Eli Lilly's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 8.48%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Eli Lilly's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 6.98%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Eli Lilly's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.32%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.19, caution is advised due to increased financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Assessing Eli Lilly: Insights From 7 Financial Analysts

Wells Fargo analyst Mohit Bansal maintains Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Overweight and lowers the price target from $1000 to $970.

Price Target

Wells Fargo Maintains Overweight on Eli Lilly, Lowers Price Target to $970

Citigroup analyst Peter Verdult maintains Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Buy and lowers the price target from $1250 to $1190.

Citigroup Maintains Buy on Eli Lilly, Lowers Price Target to $1190

A Google parent-owned startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end, marking a significant milestone in pharmaceutical development as major tech companies increasingly invest in AI-powered healthcare solutions.
What Happened: Isomorphic Labs, an Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) subsidiary, is targeting major disease areas including oncology, cardiovascular conditions, and neurodegeneration, founder Demis Hassabis <a href="https://www.ft.com/content/41b51d07-0754-4ffd-a8f9-737e1b1f0c2e">told</a> Financial Times, speaking at the World Economic Forum in Davos. 
The company has already secured partnerships with Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) for six drug development programs.
&#8220;It usually takes an average of five to 10 years to discover one drug. And maybe we could accelerate that 10 times, which would be an incredible revolution in human health,&#8221; said Hassabis, who recently received the Nobel Prize in Chemistry.
See Also: <a href="https://www.benzinga.com/markets/equities/25/01/43119464/netflix-raises-prices-16-peter-schiff-warns-of-escalating-inflation-risks-ahead-of-trump-policies">Netflix Raises Prices 16%, Peter Schiff Warns Of Escalating Inflation Risks Ahead Of Trump Policies</a>
Why It Matters: The announcement comes as Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) unveiled plans for an AI-driven cancer vaccine system capable of delivering personalized treatments within 48 hours. The initiative is <a href="https://www.benzinga.com/markets/equities/25/01/43118941/oracles-larry-ellison-says-cancer-vaccine-tailored-in-48-hours-could-soon-be-a-reality-as-trump-announces-500-billion-ai-investment">part of a $500 billion AI infrastructure project</a> called Stargate, developed in partnership with OpenAI and SoftBank Group.
Investment in AI-powered drug discovery has gained momentum, with ARK Invest CEO Cathie Wood projecting a $400 billion market opportunity in <a href="https://www.benzinga.com/general/biotech/24/11/42206182/cathie-wood-sees-400b-opportunity-in-biologics-how-have-her-bets-fared">biologics over the next five years</a>. The sector has attracted significant attention from investors, though companies like Crispr Therapeutics AG and Intellia Therapeutics Inc. have shown considerable market volatility.
Isomorphic Labs, spun out from Google DeepMind in 2021, represents a growing trend of tech giants leveraging AI to streamline the traditionally lengthy and expensive drug development process. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/43119243/martin-shkreli-calls-ionq-and-rigetti-best-shorts-despite-recent-stock-gains-cites-offline-quantum-systems">Martin Shkreli Calls IonQ And Rigetti &#8216;Best Shorts&#8217; Despite Recent Stock Gains, Cites Offline Quantum Systems</a></li>
</ul>
Image Via Shutterstock 
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

CRSP

GOOGL

NTLA

ORCL

Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases

Shares of Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) are trading higher after getting pummeled on Friday. The move lower happened after the company announced preliminary sales that were less than expected. The sales were $45 billion and investors were <a href="https://www.benzinga.com/general/biotech/25/01/43013223/eli-lilly-adjusts-outlook-ceo-david-ricks-explains-revenue-shortfall">looking for $46 billion.</a>
There's a good chance that the move lower is over. There is also a good chance that the stock is about to rebound. This is why our team of technical analysts and traders has made it our Stock of the Day.
As you can see on the chart, there has been support around $722.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="546" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21111541/lly-1024x546.png" alt="" class="wp-image-742967" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21111541/lly-1024x546.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21111541/lly-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21111541/lly-768x409.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21111541/lly.png 1522w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
If a stock is trending lower, there is more supply (sell orders) than there is demand (buy orders). Those who wish to sell are forced to offer their shares at a discount to draw buyers into the market. This pushes the stock into a downtrend.
At a support level, the dynamic changes. There is enough demand to absorb all of the supply. This puts a floor under the price.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43097512/apples-ai-advances-cant-offset-chinese-market-slowdown-says-analyst">Apple&#8217;s AI Advances Can&#8217;t Offset Chinese Market Slowdown, Says Analyst</a>
Support levels can stay intact for an extended period of time because of remorseful sellers.
There are traders and investors who sold shares for around $722 in March who regretted doing so when the stock rallied soon after. Some of them decided that if they could, they would buy their shares back at the same price they were sold for.
So, when the stock returned to around the $722 level in April they placed buy orders. The large number of these buy orders caused support to form at the same price that had been support before.
Similar price action occurred in November.
Regretful traders and investors who sold around $722 in April placed buy orders to get their shares back at their selling prices. The large number of these orders created support at the level again.
As you can see, each time Lilly found this support a move higher followed. On Friday, the stock found support at the level once again. The stage may be set for another rebound.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43098429/netflix-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Netflix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>
Photo: Shutterstock

Technicals

Stock Of The Day: Lilly's Strong Support Level Signals Potential Rebound

These eleven large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>FTAI Aviation Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) shares plummeted 35.42% after short seller firm Muddy Waters Research announced they <a href="https://www.benzinga.com//node/43040046" target="_blank" rel="noreferrer noopener">initiated a short position in the company</a>.</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) stock plunged 19.38% after the company updated its 2025 expected revenue range to $1.5 billion to $2.5 billion, below <a href="https://www.benzinga.com//node/42946454" target="_blank" rel="noreferrer noopener">analyst estimates of $2.951 billion</a>. Morgan Stanley maintained an Equal-Weight rating and lowered the <a href="https://www.benzinga.com/quote/mrna/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from $70 to $38</a>.</li>
<li>GameStop Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) stock declined 14.86%. In a recent X post, CNBC's Jim Cramer <a href="https://www.benzinga.com//node/43053808" target="_blank" rel="noreferrer noopener">steered investors toward</a> quantum stocks, suggesting they reinvest gains from GameStop into Rigetti Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>).</li>
<li>Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) shares dipped 12.91% following a report suggesting that Trump is considering an executive order to save TikTok from a U.S. ban.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) shares were down 10.81%. The company disclosed that its second Pioneer spacecraft for Varda Space Industries, Inc. is<a href="https://www.benzinga.com//node/43028933" target="_blank" rel="noreferrer noopener"> successfully operating in orbit</a>.</li>
<li>Natera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) stock lost 9.51% last week despite Guggenheim <a href="https://www.benzinga.com/quote/ntra/analyst-ratings" target="_blank" rel="noreferrer noopener">raising the price forecast</a> from $170 to $200. The company is due to provide a roadmap and outlook at the J.P. Morgan Healthcare Conference.</li>
<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) stock decreased 9.27%  after the company issued FY24 revenue guidance <a href="https://www.benzinga.com//node/42976923" target="_blank" rel="noreferrer noopener">below the previous estimate</a>.</li>
<li>ICON plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) stock fell 9.22% after the company issued FY25 guidance with <a href="https://www.benzinga.com//node/42971328" target="_blank" rel="noreferrer noopener">its midpoint below estimates</a>.</li>
<li>BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) shares declined 8.89% after Moderna issued 2025 revenue <a href="https://www.benzinga.com//node/42951363" target="_blank" rel="noreferrer noopener">guidance below analyst estimates</a>.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) shares fell 8.89% after Ozempic and Wegovy were included in a list of 15 medications for <a href="https://www.benzinga.com//node/43062779" target="_blank" rel="noreferrer noopener">Medicare drug price negotiations</a>.</li>
<li>BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) shares tumbled 8.68%. The company initiated a legal action against Ascendis Pharma A/S for infringement of European patent EP 3 175 863 B1 at the <a href="https://www.benzinga.com//node/42953403" target="_blank" rel="noreferrer noopener">Unified Patent Court (UPC) in Munich, Germany</a>.</li>
</ol>
Photos courtesy: Shutterstock

Short Sellers

BMRN

BNTX

FTAI

ICLR

MRNA

NTRA

RKLB

SNAP

Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?

President Joe Biden prioritized <a href="https://www.benzinga.com/markets/cannabis/25/01/43054504/biden-commutes-sentences-of-nearly-2500-convicted-of-non-violent-drug-offenses-no-mention-of-cannabis-prisoners">freeing non-violent drug offenders</a> during his final few days in the White House, but TikTok? That's President-elect Donald Trump's problem now. 
According to the <a href="https://apnews.com/article/tiktok-ban-trump-executive-order-1e95d9836bf6f8c0c245ed1c3234d968">Associated Press</a>, Biden has no intention of enforcing the ban, which takes effect on his last full day in office, Jan. 19, and one day <a href="https://www.benzinga.com/news/25/01/42995328/trump-inauguration-from-elon-musk-jeff-bezos-to-barack-obama-george-bush-and-bill-clinton-who-all-will-attend">before Trump&#8217;s inauguration</a>.
With a deadline looming, the app's fate lands in the hands of the so-called People's Bid for TikTok—backed by none other than Kevin O'Leary of &#8220;Shark Tank&#8221; and billionaire Frank McCourt. Apparently, TikTok's U.S. assets are still up for grabs, but no word yet on the price tag or whether a deal can realistically get done <a href="https://www.benzinga.com/general/social-media/25/01/43060894/supreme-court-upholds-tiktok-ban-ahead-of-trumps-inauguration">in a few days</a>.
<h2 class="wp-block-heading">Bankruptcy Block</h2>
Joann Inc. is stitching together a bankruptcy plan for the second time within 12 months. The Ohio-based fabric and crafts retailer is seeking a buyer for its portfolio of some 800 stores. 
Gordon Brothers Retail Partners emerged as the &#8220;stalking horse&#8221; bidder, but Joann remains hopeful for better offers—perhaps from someone who knows how to thread the needle.
Previously, the 82-year-old retailer was under the stewardship of private equity firm Leonard Green &amp; Partners, which acquired it via a $1.6 billion leveraged buyout in 2011. The firm buried the company under a pile of debt (<a href="https://wolfstreet.com/2024/03/18/brick-and-mortar-meltdown-fells-another-retailer-joann-inc-files-for-bankruptcy-3-years-after-ipo/">reportedly</a> $921 million in long-term debt as of Oct. 31, 2020) and <a href="https://www.benzinga.com/news/21/03/20048728/ipo-preview-roblox-coupang-joann-lead-busy-week-of-offerings">sent it public in 2021</a>. 
Joann went private again in <a href="https://apnews.com/article/joann-bankruptcy-chapter-11-filing-75093d4032907c59a45e472dd4e23229">March</a> 2024 while under Chapter 11 bankruptcy protection. The company managed to reduce its $1 billion total debt by about $500 million at the time.
Despite efforts to save itself last year, Joann is joining the growing quilt of recent retail casualties: Party City, Big Lots, LL Flooring, The Body Shop and The Container Store <a href="https://www.benzinga.com/news/legal/24/12/42710619/deal-dispatch-party-city-wraps-big-lots-goes-bust-container-store-continues">to name a few</a>.
Kirkland &amp; Ellis is handling legal matters, while Centerview Partners LLC offers financial advice. Alvarez &amp; Marsal North America, LLC is overseeing the restructuring process.
<h2 class="wp-block-heading">New On The Block</h2>
<ul>
<li>Investment firm KKR &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) hired Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) to run an auction for its minority stake in Philippine fintech company Maya, Reuters reported. </li>
<li>New York-headquartered KKR owns more than 20% of Maya and the potential sale, if it goes through, could value Maya at more than $2 billion, one of the sources said.</li>
<li>DuPont de Nemours, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) is looking to <a href="https://www.benzinga.com/news/large-cap/25/01/43028181/chemical-company-dupont-electronics-business-separation-retains-water-business">jettison its electronics business</a>. The Wilmington, Delaware-based company expects the transaction to be completed by Nov. 1. DuPont also decided to retain its water business after evaluating strategic alternatives.</li>
<li>Ingevity Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) is shopping its Performance Chemicals Industrial Specialties segment, which includes divesting parts of its North Charleston, South Carolina site. The company hopes to improve earnings cash flow and conclude the review process by year-end. Whether a transaction comes about <a href="https://www.benzinga.com/news/25/01/43027745/ingevity-explores-strategic-options-for-performance-chemicals-segment-to-strengthen-portfolio-projects-fy24-revenue-at-1-40-billion">remains to be seen</a>. </li>
<li>S&amp;W Seed Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>) is up for sale. It&#8217;s also considering a merger or recapitalization as part of a larger strategic review. The Longmont, Colorado-based company has already sold its Australia subsidiary. &#8220;We continue to support all initiatives that optimize shareholder value and will consider the full range of potential strategic alternatives to ensure S&amp;W Seed is best positioned for future success,&#8221; chairman Alan Willits said.</li>
</ul>
See Also: <a href="https://www.benzinga.com/25/01/43046722/starship-explodes-during-flight-test-elon-musk-says-success-is-uncertain-but-entertainment-is-guaranteed">Starship Explodes During Flight Test, Elon Musk Says: &#8216;Success Is Uncertain, But Entertainment Is Guaranteed!&#8217;</a>
<h2 class="wp-block-heading">Updates From The Block</h2>
<ul>
<li>Lourenco Goncalves raised eyebrows during a Monday press conference. According to <a href="https://www.bloomberg.com/news/articles/2025-01-14/cliffs-ceo-rips-evil-japan-and-doubles-down-on-america-first">Bloomberg</a>, the CEO of Cleveland-Cliffs Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) called Japan, a U.S. ally, &#8220;evil&#8221; and accused it of teaching China harmful practices like dumping and overproduction. His comments came as Cleveland-Cliffs eyes a new bid for U.S. Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>), following Biden&#8217;s decision to block Nippon Steel&#8216;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NPSCY#OTC">NPSCY</a>) <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42787508/biden-blocks-14-9b-us-steel-takeover-shares-plunge">$14 billion acquisition attempt</a>. While positioning his company as a potential buyer, Goncalves&#8217; rhetoric escalated tensions within the steel industry. Nippon is now looking to Trump to <a href="https://www.benzinga.com/news/25/01/42994950/nippon-steel-eyes-trump-administration-to-revive-15b-us-steel-deal-blocked-by-biden-well-do-whatever-it-takes">help close the deal</a>. </li>
<li>T-Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) will buy Vistar Media for $600 million. The telecom company expects the deal to strengthen its advertising business, Reuters reported. </li>
</ul>
Deals in the biotech and pharmaceutical sectors piled up this week. Here&#8217;s a sample of Benzinga&#8217;s coverage:
<ul>
<li>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) submitted an unsolicited bid to acquire all of the outstanding shares of Sage Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) that it does not already own <a href="https://www.benzinga.com/25/01/42957657/biogens-push-for-sage-therapeutics-could-strengthen-its-neurology-strategy-analysts-say">for $7.22 per share</a>. Goldman Sachs analyst Salveen Richter believes the proposal makes strategic sense, considering the financial success of the Zurzuvae launch for postpartum depression (PPD).</li>
<li>GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) <a href="https://www.benzinga.com/25/01/42950025/gsk-to-buy-us-based-stomach-cancer-drug-developer-for-over-1-billion">agreed to acquire</a> IDRx, Inc., a biopharmaceutical company focused on precision therapeutics for gastrointestinal stromal tumors (GIST), for $1 billion. The deal may require an additional $150 million from GSK after certain regulatory approval milestones. </li>
<li>Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) scooped up Scorpion Therapeutics&#8217; early-stage <a href="https://www.benzinga.com/25/01/42949261/eli-lilly-scoops-up-scorpion-therapeutics-early-stage-cancer-program-for-25-billion">cancer program for $2.5 billion</a>. </li>
<li>Like Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) and AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) is seeking to bolster its neuropsychiatric portfolio<a href="https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal"> with a $15 billion deal</a></li>
<li>Crown Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) offered to acquire all outstanding common shares of Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) at $3.10 per share.</li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) agreed to a deal with Decoy Therapeutics, a preclinical biotech focused on peptide conjugate therapeutics. The merged entity will target unmet needs in respiratory diseases and GI oncology.</li>
<li>Lantheus Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) strengthens its radiopharmaceutical position with<a href="https://www.benzinga.com/m-a/25/01/42937565/lantheus-strengthens-radiopharmaceutical-leadership-with-350m-acquisition-of-life-molecular-imaging"> $350 million acquisition of Life Molecular Imaging</a>.</li>
</ul>
For last week&#8217;s edition of Deal Dispatch, <a href="https://www.benzinga.com/ma/25/01/42921113/deal-dispatch-td-bank-charles-schwab-eyenovia-smart-share-hit-auction-block">click here</a>.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/real-estate/25/01/43055513/eccentric-billionaire-howard-hughes-former-miami-estate-on-market-for-55-5-million">Eccentric Billionaire, Legendary Filmmaker Howard Hughes&#8217; Former Miami Estate On Market For $55.5 Million</a></li>
</ul>
Image created with a photo from Shutterstock.

BIIB

LNTH

NGVT

NPSCY

RVNC

SAGE

SANW

SLRX

TMUS

Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt

Eli Lilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) short percent of float has risen 5.88% since its last report. The company recently reported that it has 6.10 million shares sold short, which is 0.72% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.82 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Eli Lilly Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737141312_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Eli Lilly has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Eli Lilly's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Eli Lilly's peer group average for short interest as a percentage of float is 4.17%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Ideas

How Is The Market Feeling About Eli Lilly?

<a href="https://www.cnbc.com/2025/01/17/medicare-drug-price-negotiations-list-includes-ozempic.html" title="https://www.cnbc.com/2025/01/17/medicare-drug-price-negotiations-list-includes-ozempic.html">https://www.cnbc.com/2025/01/17/medicare-drug-price-negotiations-list-includes-ozempic.html</a>

AMGN

TEVA

'Ozempic Is In The Next Round Of Medicare Drug Price Negotiations. See The Full List Of 15 Medications' - CNBC

On Wednesday, the FDA approved Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)&nbsp;Omvoh&nbsp;(mirikizumab-mrkz) for moderately to severely active Crohn&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n43015170/fda-approves-lillys-omvoh-mirikizumab-mrkz-for-crohns-disease-expanding-its-use-to-the-second-majo" rel="noreferrer noopener">disease in adults</a>.
Omvoh is now approved in the U.S. for two types of inflammatory bowel disease (IBD), following its&nbsp;October 2023&nbsp;approval as a first-in-class treatment for moderately to severely active ulcerative colitis (UC) in adults.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43013223/eli-lilly-adjusts-outlook-ceo-david-ricks-explains-revenue-shortfall" rel="noreferrer noopener">Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue Shortfall</a>
Omvoh works to reduce inflammation within the gastrointestinal tract by targeting a specific protein, interleukin-23p19 (IL-23p19), which is a key contributor to intestinal inflammation.
Omvoh is the first biologic treatment in more than 15 years to have disclosed two-year Phase 3 efficacy data in Crohn&#8217;s disease at the time of approval.
The approval is based on results from the Phase 3 VIVID-1 study. Patients randomized to placebo who did not achieve clinical response by patient-reported outcome at 12 weeks (40% of placebo patients) were subsequently switched to Omvoh treatment. Both primary endpoints in <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41314649/more-patients-on-eli-lillys-mirikizumab-achieved-histologic-response-at-one-year-compared-to-john" rel="noreferrer noopener">VIVID-1 were achieved</a>:
<ul>
<li>Clinical remission by Crohn&#8217;s Disease Activity Index (CDAI) at one year53% of patients treated with Omvoh achieved clinical remission at one year versus 36% on placebo.</li>
<li>Endoscopic response at one year46% of patients treated with Omvoh had visible healing of the intestinal lining at one year versus 23% on placebo.</li>
</ul>
Additionally, 32% of Omvoh patients achieved early improvement in endoscopic response, defined by visible healing of the intestinal lining, versus 11% on placebo at three months.
Omvoh is also being studied in VIVID-2, an ongoing, open-label extension (OLE) study evaluating the eﬃcacy and safety of Omvoh for up to three years in adults with moderately to severely <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41580394/eli-lillys-mirikizumab-shows-long-term-sustained-efficacy-safety-for-ulcerative-colitis-and-crohn" rel="noreferrer noopener">active Crohn&#8217;s disease</a>.
Among patients who achieved endoscopic response at one year in VIVID-1, over 80% maintained endoscopic response with one year of additional treatment (two years of continuous treatment).
Additionally, among patients who achieved clinical remission and endoscopic response at one year in VIVID-1, nearly 90% maintained clinical remission with one year of additional treatment (two years of continuous treatment).
Price Action: LLY stock is down 0.29% at $755.40&nbsp;during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/01/43039195/spruce-point-sees-trouble-ahead-for-procept-biorobotics" target="_blank" rel="noreferrer noopener">Spruce Point Sees Trouble Ahead For Procept BioRobotics</a></li>
</ul>
Photo via Shutterstock

FDA Approves Expanded Use Of Eli Lilly's Ulcerative Colitis Drug For Crohn's Disease

Hims & Hers Health, Inc. Class A Common Stock

HIMS

U.S. FDA Chief Califf Says Current Regulations Not Enough To Protect Americans From Risks Of Compounded GLP-1 Drugs

Deep-pocketed investors have adopted a bearish approach towards Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LLY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 52 extraordinary options activities for Eli Lilly. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable options, 11 are puts, totaling $413,328, and 41 are calls, amounting to $2,523,494.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $250.0 to $1440.0 for Eli Lilly during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Eli Lilly's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly's whale trades within a strike price range from $250.0 to $1440.0 in the last 30 days. 
<h3>Eli Lilly Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737051361_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$501.75</td>
<td>$497.6</td>
<td>$500.09</td>
<td>$250.00</td>
<td>$250.0K</td>
<td align="right">61</td>
<td align="right">5</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/24/25</td>
<td>$21.8</td>
<td>$20.4</td>
<td>$20.45</td>
<td>$735.00</td>
<td>$153.3K</td>
<td align="right">123</td>
<td align="right">75</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$20.65</td>
<td>$20.6</td>
<td>$20.6</td>
<td>$780.00</td>
<td>$109.2K</td>
<td align="right">999</td>
<td align="right">65</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$71.3</td>
<td>$69.7</td>
<td>$71.0</td>
<td>$760.00</td>
<td>$106.5K</td>
<td align="right">112</td>
<td align="right">16</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$167.5</td>
<td>$163.05</td>
<td>$165.46</td>
<td>$590.00</td>
<td>$99.2K</td>
<td align="right">142</td>
<td align="right">5</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Having examined the options trading patterns of Eli Lilly, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Eli Lilly</h3>
<ul>
<li>Trading volume stands at 1,491,322, with LLY's price up by 1.89%, positioned at $760.86.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 21 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Eli Lilly's Options: A Look at What the Big Money is Thinking

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has outperformed the market over the past 15 years by 10.74% on an annualized basis producing an average annual return of 22.68%. Currently, Eli Lilly has a market capitalization of $723.79 billion. 
Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 15 years ago, it would be worth $21,118.25 today based on a price of $762.43 for LLY at the time of writing.
<h3>Eli Lilly's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737045917_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Eli Lilly 15 Years Ago Would Be Worth Today

Eli Lilly Announces The FDA Has Approved Omvoh For The Treatment Of Moderately To Severely Active Crohn's Disease in Adults

Just before the JP Morgan healthcare conference, Eli Lilly and Co&nbsp;(NYSE:&nbsp;LLY) announced that it expects 2024 full-year worldwide revenue to be approximately&nbsp;$45.0 billion, representing a 32% growth compared to the previous year versus the&nbsp;<a target="_blank" href="https://www.benzinga.com/25/01/42976923/eli-lilly-expects-around-55-billion-sales-from-weight-lossdiabetes-drugs-with-overall-topline-growth-of-32-issues-2025-forecast" rel="noreferrer noopener">consensus of $45.50 billion</a>.
The company's expected 2024 revenue is&nbsp;$400 million, or about 3%, below the guidance range issued during the&nbsp;third-quarter earnings. The guidance includes approximately&nbsp;$3.5 billion&nbsp;for Mounjaro and $1.9 billion&nbsp;for Zepbound.
During the conference, David Ricks outlined two reasons for the guidance update:
<ul>
<li>The diabetes GLP market, in December, outperforms the rest of the quarter and in year this did not happen&#8230;The CEO said this could be just a guess. The company said it did not predict it. "This year that didn't happen in GLP-1," said Ricks, who speculated that changes in Medicare Part D and insurance edits have prevented patients from doubling up their prescriptions at the end of the year to avoid deductible costs early in the following year."</li>
<li>Stocking levels were a big discussion during Q3 results. The company dropped about 8 selling days in that quarter alone. The company expected a buildback at the end of the year because every year, a couple of days of buildback happen, and it did not happen this year.</li>
</ul>
Regarding the guidance approach, the CEO noted, "The scale of this business and the way it's been growing, the consumer part of it, along with the stocking dynamics, it's just been a learning [experience] for us," Ricks said. "Our forecasters really nailed the rest of the portfolio. We don't have a problem with forecasting. It's just, this market is quite different."
Goldman analyst Chris Shibutani writes, "We expect this preliminary 4Q results to heighten concerns relating to underlying demand dynamics, which initially emerged at a broader level amongst investors during the 3Q results and guidance update."
Price Action: LLY stock is up 0.59% at $749.28 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/01/43004444/intel-plans-to-spin-off-5-billion-venture-capital-segment-will-remain-anchor-investor" target="_blank" rel="noreferrer noopener">Intel Plans To Spin Off $5 Billion Venture Capital Segment, Will Remain Anchor Investor</a></li>
</ul>
Photo via Eli Lilly and Company

Analyst Color

Guidance

Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue Shortfall

Eli Lilly Stock's Correction Brings Opportunity

Truist analyst Srikripa Devarakonda says that in early questioning today, Robert Francis Kennedy Jr. reiterated that he does not want to "take away...

RFK Jr. comments contradict anti-vaccine legacy, says Truist

HHS Secretary nominee RFK Jr. faces contentious Senate hearing

Wells Fargo analyst Mohit Bansal downgraded Vertex Pharmaceuticals (VRTX) to Equal Weight from Overweight with an unchanged price target of $460. T...

Wells downgrades Vertex to Equal Weight on lack of catalysts

Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data

Foghorn Therapeutics a new buy at B Riley on tumor fighting technology

RFK Jr. hails GLP-1 weight loss meds as 'miracle drugs'

Tectonic Therapeutic: Stock Spikes On Heart Failure Data -- Why I See Further Upside

Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance

What we got today, of course, was advance GPD, which is the earliest measure and also the most likely to provoke a reaction in stocks.

How We Can Trade On GDP

ALPMF

ALPMY

ATAI

CMPS

CYBN

DNLI

DRUG

FHTX

GHRS

GILD

MNMD

NONOF

NVAX

RHHBF

RHHBY

RHHVF

SGMO

SRRK

TECX

VRTX

VYGR

Screenshot 2024-11-20 at 6.30.30 PM

BRTX

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-24 at 12.03.42 AM

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Screenshot 2024-02-22 at 11.51.01 PM

BTTX

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Press Releases

Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)

Opinion

Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments

Indiana Sees $39 Billion Worth of Projects Under Construction, an Industrial Info News Alert

FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity

Lilly to participate in J.P. Morgan Healthcare Conference

Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program

Earnings

Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance

FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease

Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement

Comments

Eli Lilly

Noticias

Últimas noticias sobre Eli Lilly (NYSE:LLY) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL